CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder
CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder
复制标题
DOI：
10.1111/j.1442-2042.2012.03128.x
复制
发表时间：
2013-02-01
影响因子：
2.6
通讯作者：
Kim, Young-Sik
中科院分区：
文献类型：
--
作者：
Choi, Jung-Woo;Kim, Younghye;Kim, Young-Sik
本研究旨在确定高CD74表达的膀胱癌患者的临床病理学特征，因为米拉珠单抗人源化抗CD74抗体正在血液恶性肿瘤的临床试验中进行评价。应用免疫组化和免疫印迹法分别检测了342例膀胱尿路上皮癌和2株尿路上皮癌细胞系中CD74的表达。CD74在342个癌组织中的192个（56.1%）中过表达，尽管其在癌细胞系中不表达。CD74在肿瘤细胞和肿瘤间质中的炎性细胞中表达较强，而在正常尿路上皮中不表达。CD74表达与诊断时年龄较大（68岁，P=0.048）、世界卫生组织分级高（P=0.019）、晚期（P=0.001）和非乳头状生长模式（P=0.040）显著相关。CD74表达与肿瘤浸润性炎性细胞的缺乏也相关（P
This study aimed to identify the clinicopathological features of bladder cancer patients with high CD74 expression, as milatuzumab humanized anti-CD74 antibody is being evaluated in clinical trials for hematological malignancies. Expression of CD74 was examined in 342 urothelial carcinomas of the bladder, and two urothelial carcinoma cell lines by immunohistochemistry and western blotting, respectively. CD74 was overexpressed in 192 (56.1%) of the 342 cancer tissues, although it was not expressed in the cancer cell lines. CD74 staining was intense in tumor cells and inflammatory cells in the tumor stroma, but not in normal urothelium. CD74 expression was significantly associated with older age at diagnosis (68years, P=0.048), high World Health Organization grade (P=0.019), advanced stages (P=0.001) and non-papillary growth pattern (P=0.040). CD74 expression was also correlated with the absence of tumor-infiltrating inflammatory cells (P